News Chart Genome & Company

Equities

A314130

KR7314130006

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
8,920 ^KRW	-2.62%		+16.91%	-28.58%

Jan. 24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
2023	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI

f024acf5339c202d7da149e6847b2ac.vlNRedRf2CjEbdFXfb0OVYC01tuVB-ZZ9WTRnECEX8I.7CIjKrANh2yCX6IwGIRpYsfnl6H_N7kBhDah_g3lBpuNZAQ6-Q2bWZcfpg~7c501857d58274612bfb1529d5b02ffc